Tumor mutational burden as a pan-cancer biomarker for immunotherapy: the limits and potential for convergence
A recent study in The Lancet Oncology reports that high tumor mutational burden (TMB) is associated with response to anti-PD-1 pembrolizumab, leading to the second FDA approval of a tissue-agnostic predictive biomarker for immunotherapy in solid tumors. This is a step forward in realizing the full p...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
November 9, 2020
|
| In: |
Cancer cell
Year: 2020, Volume: 38, Issue: 5, Pages: 624-625 |
| ISSN: | 1878-3686 |
| DOI: | 10.1016/j.ccell.2020.10.019 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ccell.2020.10.019 Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S153561082030550X 
|
| Author Notes: | Antonio Passaro, Albrecht Stenzinger, and Solange Peters |
| Summary: | A recent study in The Lancet Oncology reports that high tumor mutational burden (TMB) is associated with response to anti-PD-1 pembrolizumab, leading to the second FDA approval of a tissue-agnostic predictive biomarker for immunotherapy in solid tumors. This is a step forward in realizing the full potential of cancer immunotherapy. |
|---|---|
| Item Description: | Gesehen am 02.02.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1878-3686 |
| DOI: | 10.1016/j.ccell.2020.10.019 |